Search

Your search keyword '"Lussier, Firoza"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Lussier, Firoza" Remove constraint Author: "Lussier, Firoza" Database Complementary Index Remove constraint Database: Complementary Index
170 results on '"Lussier, Firoza"'

Search Results

1. Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts.

2. Tau follows principal axes of functional and structural brain organization in Alzheimer's disease.

3. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer's disease.

4. Reduction in Constitutively Activated Auditory Brainstem Microglia in Aging and Alzheimer's Disease.

5. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females.

6. Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging.

7. Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals.

8. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.

9. Neuroinflammation Exacerbates Irritability and Agitation in Alzheimer's Disease.

10. Microglial Activation Contributes to Neuropsychiatric Dysfunction in Alzheimer's Disease.

11. Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes.

12. Potential utility of using both APOEε4 and Aβ positivity to enrich clinical trials of tau‐targeting therapies.

13. APOEε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation.

14. The impact of young controls in the detection of tau load in cognitively impaired and asymptomatic elderly.

15. Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer's disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction related to cognitive impairment.

16. Sex modulates the role of astrocyte reactivity in preclinical Alzheimer's disease.

17. Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer's disease.

18. Plasma p‐tau231 and p‐tau217 provides information on tau tangle deposition in symptomatic Alzheimer's disease individuals.

19. Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer's disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction related to cognitive impairment.

20. Neuroinflammation Exacerbates Irritability and Agitation in Alzheimer's Disease.

21. Microglial Activation Contributes to Neuropsychiatric Dysfunction in Alzheimer's Disease.

22. Potential utility of using both APOEε4 and Aβ positivity to enrich clinical trials of tau‐targeting therapies.

23. APOEε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation.

24. Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes.

25. Sex modulates the role of astrocyte reactivity in preclinical Alzheimer's disease.

26. Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer's disease.

27. Plasma p‐tau231 and p‐tau217 provides information on tau tangle deposition in symptomatic Alzheimer's disease individuals.

29. Plasma and CSF concentrations of N‐terminal tau fragments associate with in vivo neurofibrillary tangle burden.

30. 14-3-3 ζ/δ-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2.

31. Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.

32. Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum.

33. Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals.

34. Blood‐brain barrier integrity impacts the use of plasma amyloid‐β as a proxy of brain amyloid‐β pathology.

36. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.

37. Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET.

38. Increased Genetic Risk for ADHD Potentiates Cognitive Impairment and Brain Hypometabolism in Alzheimer's Disease Patients.

40. Assessment of quantitative susceptibility mapping (QSM) and oxygen extraction fraction (OEF) in the spectrum of Alzheimer's disease clinical presentations.

41. Interactions of synaptic and inflammatory biomarkers in Alzheimer's Disease.

42. Fast accumulators of tau have higher levels of plasma pTau and stronger associations with amyloid in later Braak regions at baseline.

43. Association of reactive astrogliosis and microglial activation with tau pathology in Alzheimer's disease.

44. Astrocyte reactivity potentiates longitudinal tau tangle accumulation in cognitively unimpaired individuals.

46. CSF total tau is more closely associated with synaptic dysfunction than overt neurodegeneration.

47. Synapse dysfunction and astrocyte reactivity are associated independently of amyloid‐β and tau pathologies.

48. Sex impacts the association of plasma Glial Fibrillary Acidic Protein with neurodegeneration in Alzheimer's disease.

49. Plasma biomarkers as stand‐alone tests in the diagnosis of Alzheimer's disease.

50. Plasma p‐tau and brain‐derived total tau biomarkers predict longitudinal changes in Aβ, tau, and cognition across the AD continuum.

Catalog

Books, media, physical & digital resources